Selling, General, and Administrative Costs: Pfizer Inc. vs Halozyme Therapeutics, Inc.

A Tale of Two Giants: Pfizer Inc. vs. Halozyme Therapeutics, Inc.

In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry leaders is crucial. This chart offers a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Pfizer Inc. and Halozyme Therapeutics, Inc., from 2014 to 2023.

Pfizer, a titan in the industry, consistently reported SG&A expenses exceeding $10 billion annually, reflecting its expansive global operations and marketing efforts. In contrast, Halozyme, a smaller yet innovative company, showed a steady increase in SG&A costs, peaking at approximately $149 million in 2023, a significant rise from $36 million in 2014.

This comparison highlights the stark contrast in scale and strategy between a pharmaceutical giant and a nimble biotech firm. As Halozyme's expenses grew by over 300% in this period, it underscores the company's aggressive push for market presence and innovation.